Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

Stay informed on the project!

News
13 January 2024

PANCAID’s 3rd General Assembly Meeting

We’re looking forward to PANCAID’s 3rd General Assembly Meeting later this week in Brussels, Belgium! 🇧🇪

The meeting is a key moment for all partners to come together, review our progress, and plan the next steps in our mission to improve early detection of pancreatic cancer.

We’ll kick off with a Stakeholder Event at the European Parliament, bringing together key policymakers, patients and experts to discuss the importance of joint efforts on early detection of pancreatic cancer.

We look forward to seeing you soon!

News
19 January 2024

PANCAID’s 2024 in Review: A Year of Impact and Progress

As the year comes to a close, let’s take a moment to reflect on our achievements of 2024. This year has been one of progress, collaboration, and impactful work in the journey against pancreatic cancer. Here are some of the highlights:

Four Scientific Review Articles Published

PANCAID published four comprehensive review articles in renowned journals, covering topics:

  • The potential of multibiomarker panels in liquid biopsies for early pancreatic cancer detection.
  • The importance of economic evaluations in pancreatic cancer screening.
  • Insights from screening high-risk populations and how this informs approaches for the general population.
  • The role of incidental findings in pancreatic cancer diagnosis and how liquid biopsy could revolutionize the field.

Our Video Series: Raising Awareness

We launched a video series to make complex information about pancreatic cancer and the project accessible to a broader audience. From explaining “What is pancreatic cancer?” to discussing Liquid Biopsy, these videos are to help spread awareness about this challenging disease.

Collaborative Efforts

2024 was also a year of collaboration. From exploring opportunities for joint dissemination activities with other Horizon Europe projects to everyday collaboration with our partners, these partnerships strengthen our mission and amplify the impact of our work.

As we look ahead to 2025, we are filled with gratitude for the support and engagement of our community, partners, and followers. Together, we are making strides toward a future where pancreatic cancer can be detected earlier and treated more effectively. PANCAID wishes each and everyone a wonderful holiday season and a successful start to the new year.

Event
20 January 2025

Reflecting on PANCAID’s 3rd General Assembly and Stakeholder Dialogue Event

PANCAID recently celebrated a milestone by organising its first Stakeholder Dialogue Event at the European Parliament in Brussels, followed by its 3rd General Assembly Meeting. These events brought together policymakers, patients, clinicians, and researchers to advance our mission of early pancreatic cancer detection.

Stakeholder Dialogue Event Highlights

Organised by PCE and with support from UEG – United European Gastroenterology, the event featured:

  • Welcome Messages: From MEP Nicolás González Casares and Malta’s Minister for Health, Jo Etienne Abela.
  • Project Insights: Updates by Prof. Klaus Pantel, supported by Dr. Ioannis Vouldis from the European Commission.
  • Patient Stories: Moving testimonies that reinforced our mission.
  • Roundtable Discussions: Experts and policymakers strategized on early detection.
  • Research Networking: Nuria Malats introduced the PCE Research Map to foster collaboration.

The event provided a vital platform for dialogue and strengthened the foundation for future initiatives.

General Assembly Highlights

Over two days, PANCAID partners reviewed progress, shared ideas, and planned ahead:

  • Early Career Scientists: Young researchers presented their work and received feedback, showcasing their dedication and innovation.
  • Work Package Updates: Progress was shared across key areas, including liquid biopsy analysis, data management, and health economics.
  • Keynote Lecture: Philipp Osten explored ethical challenges in cancer research, providing a thoughtful conclusion to the meeting.

Thank you to everyone who participated—we look forward to continuing this journey together!

About

PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 18 members from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more